Efficacy and Tolerability of a Probiotic Ointment
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Sofia Nordh, PhD
- 전화번호: +46 (0)8 555 293 00
- 이메일: son@biogaianewsciences.com
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria Male and female pediatric patients aged 0.5 years to 15 years with Atopic Dermatitis.
SCORAD Index at D0 = 15 to 50, inclusive. In goodgeneral health as reported by the parent(s)/legal representative(s). Available for the full duration of the study and willing to comply with procedures.
Subjects whose parents or legal representative are willing to sign the informed consent.
Exclusion Criteria Use of phototherapy for atopic dermatitis. Use of systemic corticosteroids within 2 weeks prior to the study. Use of Immunosuppressive or cytostatic drugs within 1 months prior to the study.
Use of antibiotics (topical and systemic) within 15 days prior to the start of the study.
Subjects who are treated with vitamin A-derived compounds or other topical medications for acne in the experimental area during the 30 days prior to the start of the study.
History of sensitivity to the study products, or its components. History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
Subjects with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days before baseline participation in any study that would interfere with the current study.
Fever (temperature> 37.5 °C axillary or equivalent) during 48 hours prior the start of the study.
Pathologies associated with immunodeficiency or cancer processes. Any concurrent dermatologic or medical conditions that may interfere with the investigators ability to assess the subject's response to the study drug or require the continued use of topical corticosteroids.
Subjects who have received the schedule MMR vaccination during the study period or have received the last dose within three weeks prior the start of the study.
Subjects who participates in any study that would interfere with the current study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Probiotic Ointment
Probiotic Ointment 2x day
|
Probiotic ointment
|
|
실험적: Comparator Product
Comparator product 2x day
|
Basic lotion
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Endpoint
기간: 28 days
|
To evaluate the change in SCORAD from baseline to Day 28.
|
28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Secondary Endpoint
기간: 14 days
|
To evaluate the change in SCORAD from baseline to Day 14
|
14 days
|
|
Secondary Endpoint
기간: 14 and 28 days
|
To evaluate the change in local SCORAD from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
기간: 14 and 28 days
|
To evaluate the change in skin barrier function (TEWL) from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
기간: 14 and 28 days
|
To evaluate the change in POEM score from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary endpoint
기간: 14 and 28 days
|
To evaluate the change in itch NRS from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
기간: 28 days
|
To evaluate the use of topical corticosteroids during the study period
|
28 days
|
|
Secondary Endpoint
기간: 28 Days
|
To explore changes in skin microbiota between baseline and Day 28
|
28 Days
|
|
Secondary Endpoint
기간: 28 days
|
To evaluate patient-reported tolerability and reported adverse events during the study period
|
28 days
|
공동 작업자 및 조사자
스폰서
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .